Biomolecules · 2019 · 30 citations · 43 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryStructure-activity RelationshipsSynthetic Medicinal ChemistryAntiparasitic AgentsAntiparasitic PharmacologyAntiparasitic TherapyProtozoal InfectionsProtozoan Host-parasite InteractionsProtozoan PathogenesisAntileishmanial TreatmentAntiparasitic Drug DiscoveryHalf-maximal Inhibitory ConcentrationHost-parasite Drug InteractionsLeishmaniasis PathogenesisNovel Antiparasitic Compound ClassesSelectivityTreatment Of Leishmaniasis
A series of seven chalcone-thiosemicarbazones (5a–5g) were synthesized and evaluated as potential new drugs (anti-leishmanial effect). Although four of the chalcone-thiosemicarbazones are already known, none of them or any compound in this class has been previously investigated for their effects on parasites of the Leishmania genus. The compounds were prepared in satisfactory yields (40–75%) and these compounds were evaluated against promastigotes, axenic amastigotes and intracellular amastigotes of L. amazonensis after 48 h of culture. The half maximal inhibitory concentration (IC50) values of the intracellular amastigotes were determined to be in the range of 3.40 to 5.95 µM for all compounds assayed. The selectivity index showed value of 15.05 for 5a, whereas pentamidine (reference drug) was more toxic in our model (SI = 2.32). Furthermore, to understand the preliminary relationship between the anti-leishmanial activity of the chalcone-thiosemicarbazones, their electronic (σ), steric (MR) and lipophilicity (π) properties were correlated, and the results indicated that moieties with electronic withdrawing effects increase the anti-leishmanial activity. The preliminary pharmacokinetic evaluation of one of the most active compound (5e) was studied via interaction to human serum albumin (HSA) using multiple spectroscopic techniques combined with molecular docking. The results of antiparasitic effects against L. amazonensis revealed the chalcone-thiosemicarbazone class to be novel prototypes for drug development against leishmaniasis.
43
Structural Basis of the Drug-binding Specificity of Human Serum Albumin
J. Ghuman, Patricia A. Zunszain, I. Petitpas et al. · Journal of Molecular Biology · 2005 · 1.9K citations
Fernando R. Pavan, Pedro I. S. Maia, Sergio R.A. Leite et al. · European Journal of Medicinal Chemistry · 2010 · 355 citations
The Atomic Structure of Human Methemalbumin at 1.9 Å
Mark R. Wardell, Zhongmin Wang, Joseph X. Ho et al. · Biochemical and Biophysical Research Communications · 2002 · 335 citations